Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
4.2
Journals
Biology
Special Issues
Biology of Brain Tumors: State of the Art and Future...
share announcement

Biology of Brain Tumors: State of the Art and Future Directions

A special issue of Biology (ISSN 2079-7737). This special issue belongs to the section "Cancer Biology".

Deadline for manuscript submissions: 31 July 2024 | Viewed by 556

Special Issue Editor

Dr. Sonia Martial

E-Mail Website
Guest Editor
Institute for Research on Cancer and Ageing of Nice (IRCAN), Université Côte d’Azur, CNRS UMR7284, INSERM U1081, Fédération Claude Lalanne (FCL), Nice, France
Interests: medulloblastoma; lymphangiogenesis; VEGFC; angiogenesis; resistance to treatment; targeted treatment; stem cells
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are thrilled to extend an invitation to you for our forthcoming Special Issue, "Biology of Brain Tumors: State of the Art and Future Directions". Brain tumors represent a complex and diverse group of neoplastic diseases originating within the central nervous system. Their heterogeneity, spanning from benign to highly aggressive forms, presents a formidable challenge. Recent advancements in genomics, molecular biology, and experimental techniques have unveiled the intricate biological landscapes underpinning the genesis and progression of brain tumors.

This Special Issue aims to provide a platform for in-depth exploration into the fundamental biology of brain tumors. We aspire to assemble a comprehensive collection of research articles and reviews that shed light on the biological underpinnings governing the initiation, growth, and diversity of brain tumors.

In our pursuit of a deeper comprehension of brain tumors, we welcome contributions in the form of original research articles and systematic reviews. Potential research areas include, but are not limited to, the following:

  • Molecular pathways and genetic determinants orchestrating brain tumor development.
  • Intricacies of the tumor microenvironment and their roles in tumorigenesis.
  • Epigenetic modifications and their influence on brain tumor heterogeneity.
  • Emerging molecular diagnostic markers and cutting-edge techniques for their exploration.
  • Insights into the molecular heterogeneity of brain tumor subtypes.
  • Future directions in basic brain tumor biology research.

I look forward to receiving your contributions. Your contributions will play a pivotal role in advancing our understanding of the fundamental biology of brain tumors. 

Dr. Sonia Martial
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • brain tumors
  • heterogeneous diseases
  • molecular basis
  • cancer genetics
  • cancer metabolomics
  • biomarker studies
  • immunotherapy

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

22 pages, 1314 KiB  
Review
The Landscape of Pediatric High-Grade Gliomas: The Virtues and Pitfalls of Pre-Clinical Models
by Liam M. Furst, Enola M. Roussel, Ryan F. Leung, Ankita M. George, Sarah A. Best, James R. Whittle, Ron Firestein, Maree C. Faux and David D. Eisenstat
Biology 2024, 13(6), 424; https://doi.org/10.3390/biology13060424 - 7 Jun 2024
Viewed by 314
Abstract
Pediatric high-grade gliomas (pHGG) are malignant and usually fatal central nervous system (CNS) WHO Grade 4 tumors. The majority of pHGG consist of diffuse midline gliomas (DMG), H3.3 or H3.1 K27 altered, or diffuse hemispheric gliomas (DHG) (H3.3 G34-mutant). Due to diffuse tumor [...] Read more.
Pediatric high-grade gliomas (pHGG) are malignant and usually fatal central nervous system (CNS) WHO Grade 4 tumors. The majority of pHGG consist of diffuse midline gliomas (DMG), H3.3 or H3.1 K27 altered, or diffuse hemispheric gliomas (DHG) (H3.3 G34-mutant). Due to diffuse tumor infiltration of eloquent brain areas, especially for DMG, surgery has often been limited and chemotherapy has not been effective, leaving fractionated radiation to the involved field as the current standard of care. pHGG has only been classified as molecularly distinct from adult HGG since 2012 through Next-Generation sequencing approaches, which have shown pHGG to be epigenetically regulated and specific tumor sub-types to be representative of dysregulated differentiating cells. To translate discovery research into novel therapies, improved pre-clinical models that more adequately represent the tumor biology of pHGG are required. This review will summarize the molecular characteristics of different pHGG sub-types, with a specific focus on histone K27M mutations and the dysregulated gene expression profiles arising from these mutations. Current and emerging pre-clinical models for pHGG will be discussed, including commonly used patient-derived cell lines and in vivo modeling techniques, encompassing patient-derived xenograft murine models and genetically engineered mouse models (GEMMs). Lastly, emerging techniques to model CNS tumors within a human brain environment using brain organoids through co-culture will be explored. As models that more reliably represent pHGG continue to be developed, targetable biological and genetic vulnerabilities in the disease will be more rapidly identified, leading to better treatments and improved clinical outcomes. Full article
(This article belongs to the Special Issue Biology of Brain Tumors: State of the Art and Future Directions)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop